Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,590 across all filing types
Latest filing 2026-05-21 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于完成工商变更登记并换发营业执照的公告
Share Issue/Capital Change Classification · 95% confidence The document is a corporate announcement by 特一药业集团股份有限公司 regarding the completion of industrial & commercial registration changes—including an increase in registered capital from 51,256.5434 万元 to 51,330.9812 万元—and the reissuance of the business license. It specifically details a capital change and provides the updated registered capital figures. This fits the "Share Issue/Capital Change" category, Code: SHA.
2026-05-21 Chinese
关于提前归还可转债暂时补充流动资金的募集资金的公告
Capital/Financing Update Classification · 92% confidence The document is a standalone corporate announcement detailing the company’s use of idle convertible bond proceeds to supplement liquidity and the subsequent early repayment of those funds. It is not an annual or interim report, nor a simple notice of report publication. It reports on financing activities (use and repayment of raised funds), fitting the “Capital/Financing Update” category.
2026-05-11 Chinese
2025年度独立董事述职报告（赖瀚琪）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2025 by an independent director of the company. It details the director's attendance at board and shareholder meetings, committee participation, supervision of company governance, and protection of shareholder rights. It is a narrative report on the director's duties and activities during the year, not a financial report, audit, or announcement. It does not contain financial statements or earnings data, nor is it a notice or announcement of a meeting or vote. This type of document fits best under Board/Management Information (MANG), as it relates to management and board activities and reporting by a director.
2026-03-23 Chinese
董事、高级管理人员离职管理制度
Governance Information Classification · 95% confidence The document is a detailed internal policy titled '董事、高级管理人员离职管理制度' (Management System for Resignation of Directors and Senior Management) of a company. It outlines procedures, responsibilities, restrictions, and obligations related to the resignation and departure of directors and senior management personnel. It references relevant laws and regulations but does not contain financial data, financial results, or any report-type content. It is a governance-related document focused on internal rules and management practices concerning board and senior management personnel. Therefore, it fits best under the category of Governance Information (CGR). The document length is 4317 characters, which is relatively short but contains substantive governance content rather than being a mere announcement or certification.
2026-03-23 Chinese
非经营性资金占用及其他关联资金往来情况汇总表的专项审计报告
Regulatory Filings
2026-03-23 Chinese
董事会对独立董事独立性自查情况的专项报告
Governance Information Classification · 95% confidence The document is a special report from the board of directors assessing the independence of the company's independent directors, referencing regulatory requirements from the Shenzhen Stock Exchange and related guidelines. It is a focused governance-related report on director independence rather than a general annual report, financial statement, or announcement of voting results. The content aligns with governance practices and internal board oversight rather than financial or capital market activities. Therefore, the most appropriate classification is Governance Information (CGR). The document length is short but contains substantive content, not merely an announcement or certification, so it is not RPA or RNS.
2026-03-23 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.